Clinical evaluation of piperacillin/tazobactam

黄海辉,张婴元,吴菊芳,汪复,钮善福,何礼贤,胡必杰,华尔铨,叶古祥,刘珂

DOI: https://doi.org/10.3969/j.issn.1001-8689.2001.04.010

2001-01-01

Abstract:Objective: To evaluate the effiacy and safety of piperacillin/tazobactam. Methods: A randomized controlled study was conducted in patients with lower respiratory tract and abdominal and biliary tract infections, 54 patients received piperacillin/tazobactam as treatment group and 52 patients received ticarcillin/clavulanic acid as control group, another 58 patients with lower respiratory tract infections, urinary tract infections, septicemia, skin and soft tissue infections were treated with piperacillin/tazobactam as open group. The dosage of piperacillin/tazobactam was 4.5g q8h in treating lower respiratory tract and abdominal and biliary tract infections, 4.5g bid in treating urinary tract infections and skin and soft tissue infections while the dosage of ticarcillin/clavulanic acid was 3.2g q8h. Results: The effective rate of treatment group in respiratory tract infections and abdominal and biliary tract infections was similar to that of control group, but the clinical efficacy of piperacillin/tazobactam in treating respiratory tract infections was better than that of ticarcillin/clavulanic acid group (P=0.02). The bacterial eradication rate was similar between two groups. There was no adverse reaction in the two groups. The total effective rate was 92.0% (103/112), the bacterial eradication rate was 97.3% (108/111), incidence of adeverse reactions was 1.8% (2/112), including 1 diarrhea and 1 slight elevation of serum ALT value. Conclusion: The efficacy of domestic piperacillin/tazobactam in treating common bacterial infections was reliable, the adverse reactions was rare and mild. The efficacy of piperacillin/tazobactam is similar to or better than ticarcillin/clavulanic acid, the safety of piperacillin/tazobactam is similar to ticarcillin/clavulanic acid.